Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Rezacova, P; Lescar, J; Brynda, J; Fabry, M; Horejsi, M; Sedlacek, J; Bentley, GA
   Structural basis of HIV-1 and HIV-2 protease inhibition by a monoclonal antibody
   STRUCTURE
   
   P. Rezacova et al., "Structural basis of HIV-1 and HIV-2 protease inhibition by a monoclonal antibody", STRUCTURE, 9(10), 2001, pp. 887-895
2. Marastoni, M; Bazzaro, M; Salvadori, S; Bortolotti, F; Tomatis, R
   HIV-1 protease inhibitors containing an N-hydroxyamino acid core structure
   BIOORGANIC & MEDICINAL CHEMISTRY
   
   M. Marastoni et al., "HIV-1 protease inhibitors containing an N-hydroxyamino acid core structure", BIO MED CH, 9(4), 2001, pp. 939-945
3. Matsumoto, H; Matsuda, T; Nakata, S; Mitoguchi, T; Kimura, T; Hayashi, Y; Kiso, Y
   Synthesis and biological evaluation of prodrug-type anti-HIV agents: Esterconjugates of carboxylic acid-containing dipeptide HIV protease inhibitorsand a reverse transcriptase inhibitor
   BIOORGANIC & MEDICINAL CHEMISTRY
   
   H. Matsumoto et al., "Synthesis and biological evaluation of prodrug-type anti-HIV agents: Esterconjugates of carboxylic acid-containing dipeptide HIV protease inhibitorsand a reverse transcriptase inhibitor", BIO MED CH, 9(2), 2001, pp. 417-430
4. Wang, L; Duan, Y; Stouten, P; De Lucca, GV; Klabe, RM; Kollman, PA
   Does a diol cyclic urea inhibitor of HIV-1 protease bind tighter than its corresponding alcohol form? A study by free energy perturbation and continuum electrostatics calculations
   JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
   
   L. Wang et al., "Does a diol cyclic urea inhibitor of HIV-1 protease bind tighter than its corresponding alcohol form? A study by free energy perturbation and continuum electrostatics calculations", J COMPUT A, 15(2), 2001, pp. 145-156
5. Melani, F; Gratteri, P; Adamo, M; Bonaccini, C
   FILO (Field Interaction Ligand Optimization): A simplex strategy for searching the optimal ligand interaction field in drug design
   JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
   
   F. Melani et al., "FILO (Field Interaction Ligand Optimization): A simplex strategy for searching the optimal ligand interaction field in drug design", J COMPUT A, 15(1), 2001, pp. 57-66
6. Pillai, B; Kannan, KK; Hosur, MV
   1.9 angstrom X-ray study shows closed flap conformation in crystals of tethered HIV-1PR
   PROTEINS-STRUCTURE FUNCTION AND GENETICS
   
   B. Pillai et al., "1.9 angstrom X-ray study shows closed flap conformation in crystals of tethered HIV-1PR", PROTEINS, 43(1), 2001, pp. 57-64
7. Israili, ZH; Dayton, PG
   Human alpha-1-glycoprotein and its interactions with drugs
   DRUG METABOLISM REVIEWS
   
   Z.H. Israili e P.G. Dayton, "Human alpha-1-glycoprotein and its interactions with drugs", DRUG METAB, 33(2), 2001, pp. 161-235
8. Buss, N; Snell, P; Bock, J; Hsu, A; Jorga, K
   Saquinavir and ritonavir pharmacokinetics following combined ritonavir andsaquinavir (soft gelatin capsules) administration
   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
   
   N. Buss et al., "Saquinavir and ritonavir pharmacokinetics following combined ritonavir andsaquinavir (soft gelatin capsules) administration", BR J CL PH, 52(3), 2001, pp. 255-264
9. Jones, K; Hoggard, PG; Khoo, S; Maher, B; Back, DJ
   Effect of alpha(1)-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro
   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
   
   K. Jones et al., "Effect of alpha(1)-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro", BR J CL PH, 51(1), 2001, pp. 99-102
10. Pellegrin, I; Breilh, D; Birac, V; Deneyrolles, M; Mercie, P; Trylesinski, A; Neau, D; Saux, MC; Fleury, HJA; Pellegrin, JL
    Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens
    THERAPEUTIC DRUG MONITORING
    
    I. Pellegrin et al., "Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens", THER DRUG M, 23(4), 2001, pp. 332-340
11. Gill, J; Feinberg, J
    Saquinavir soft gelatin capsule - A comparative safety review
    DRUG SAFETY
    
    J. Gill e J. Feinberg, "Saquinavir soft gelatin capsule - A comparative safety review", DRUG SAFETY, 24(3), 2001, pp. 223-232
12. Chiba, M; Jin, LX; Neway, W; Vacca, JP; Tata, JR; Chapman, K; Lin, JH
    P450 interaction with HIV protease inhibitors: Relationship between metabolic stability, inhibitory potency, and p450 binding spectra
    DRUG METABOLISM AND DISPOSITION
    
    M. Chiba et al., "P450 interaction with HIV protease inhibitors: Relationship between metabolic stability, inhibitory potency, and p450 binding spectra", DRUG META D, 29(1), 2001, pp. 1-3
13. Thompson, LA; Tebben, AJ
    Chapter 24. Pharmacokinetics and design of aspartyl protease inhibitors
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 36
    
    L.A. Thompson e A.J. Tebben, "Chapter 24. Pharmacokinetics and design of aspartyl protease inhibitors", ANNU REP M, 36, 2001, pp. 247-256
14. Ghosh, AK; Bilcer, G; Schiltz, G
    Syntheses of FDA approved HIV protease inhihitors
    SYNTHESIS-STUTTGART
    
    A.K. Ghosh et al., "Syntheses of FDA approved HIV protease inhihitors", SYNTHESIS-S, (15), 2001, pp. 2203-2229
15. Grub, S; Bryson, H; Goggin, T; Ludin, E; Jorga, K
    The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    
    S. Grub et al., "The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients", EUR J CL PH, 57(2), 2001, pp. 115-121
16. Zucker, SD; Qin, XF; Rouster, SD; Yu, F; Green, RM; Keshavan, P; Feinberg, J; Sherman, KE
    Mechanism of indinavir-induced hyperbilirubinemia
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    
    S.D. Zucker et al., "Mechanism of indinavir-induced hyperbilirubinemia", P NAS US, 98(22), 2001, pp. 12671-12676
17. Huisman, MT; Smit, JW; Wiltshire, HR; Hoetelmans, RMW; Beijnen, JH; Schinkel, AH
    P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir
    MOLECULAR PHARMACOLOGY
    
    M.T. Huisman et al., "P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir", MOLEC PHARM, 59(4), 2001, pp. 806-813
18. Pyring, D; Lindberg, J; Rosenquist, A; Zuccarello, G; Kvarnstrom, I; Zhang, H; Vrang, L; Unge, T; Classon, B; Hallberg, A; Samuelsson, B
    Design and synthesis of potent C-2-symmetric diol-based HIV-1 protease inhibitors: Effects of fluoro substitution
    JOURNAL OF MEDICINAL CHEMISTRY
    
    D. Pyring et al., "Design and synthesis of potent C-2-symmetric diol-based HIV-1 protease inhibitors: Effects of fluoro substitution", J MED CHEM, 44(19), 2001, pp. 3083-3091
19. Kuhelj, R; Rizzo, CJ; Chang, CH; Jadhav, PK; Towler, EM; Korant, BD
    Inhibition of human endogenous retrovirus-K10 protease in cell-free and cell-based assays
    JOURNAL OF BIOLOGICAL CHEMISTRY
    
    R. Kuhelj et al., "Inhibition of human endogenous retrovirus-K10 protease in cell-free and cell-based assays", J BIOL CHEM, 276(20), 2001, pp. 16674-16682
20. Trylska, J; Grochowski, P; Geller, M
    Parameterization of the approximate valence bond (AVB) method to describe potential energy surface in the reaction catalyzed by HIV-1 protease
    INTERNATIONAL JOURNAL OF QUANTUM CHEMISTRY
    
    J. Trylska et al., "Parameterization of the approximate valence bond (AVB) method to describe potential energy surface in the reaction catalyzed by HIV-1 protease", INT J QUANT, 82(2), 2001, pp. 86-103
21. Panchal, SC; Bhavesh, NS; Hosur, RV
    Real time NMR monitoring of local unfolding of HIV-1 protease tethered dimer driven by autolysis
    FEBS LETTERS
    
    S.C. Panchal et al., "Real time NMR monitoring of local unfolding of HIV-1 protease tethered dimer driven by autolysis", FEBS LETTER, 497(1), 2001, pp. 59-64
22. Tayrouz, Y; Ganssmann, B; Ding, R; Klingmann, A; Aderjan, R; Burhenne, J; Haefeli, WE; Mikus, G
    Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement
    CLINICAL PHARMACOLOGY & THERAPEUTICS
    
    Y. Tayrouz et al., "Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement", CLIN PHARM, 70(5), 2001, pp. 405-414
23. Verkhivker, GM; Rejto, PA; Bouzida, D; Arthurs, S; Colson, AB; Freer, ST; Gehlhaar, DK; Larson, V; Luty, BA; Marrone, T; Rose, PW
    Parallel simulated tempering dynamics of ligand-protein binding with ensembles of protein conformations
    CHEMICAL PHYSICS LETTERS
    
    G.M. Verkhivker et al., "Parallel simulated tempering dynamics of ligand-protein binding with ensembles of protein conformations", CHEM P LETT, 337(1-3), 2001, pp. 181-189
24. Ma, C; Nakamura, N; Hattori, M
    Inhibitory effects on HIV-1 protease of tri-p-coumaroylspermidine from Artemisia caruifolia and related amides
    CHEMICAL & PHARMACEUTICAL BULLETIN
    
    C. Ma et al., "Inhibitory effects on HIV-1 protease of tri-p-coumaroylspermidine from Artemisia caruifolia and related amides", CHEM PHARM, 49(7), 2001, pp. 915-917
25. Northrop, DB
    Follow the protons: A low-barrier hydrogen bond unifies the mechanisms of the aspartic proteases
    ACCOUNTS OF CHEMICAL RESEARCH
    
    D.B. Northrop, "Follow the protons: A low-barrier hydrogen bond unifies the mechanisms of the aspartic proteases", ACC CHEM RE, 34(10), 2001, pp. 790-797
26. Mallolas, J; Blanco, JL; Sarasa, M; Giner, V; Martinez, E; Garcia-Viejo, MA; Arnaiz, JA; Cruceta, A; Soy, D; Tuset, M; Soriano, A; Codina, C; Pumarola, T; Carne, X; Gatell, JM
    Dose-finding study of once-daily indinavir/ritonavir plus zidovudine and lamivudine in HIV-infected patients
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    J. Mallolas et al., "Dose-finding study of once-daily indinavir/ritonavir plus zidovudine and lamivudine in HIV-infected patients", J ACQ IMM D, 25(3), 2000, pp. 229-235
27. Aymard, G; Legrand, M; Trichereau, N; Diquet, B
    Determination of twelve antiretroviral agents in human plasma sample usingreversed-phase high-performance liquid chromatography
    JOURNAL OF CHROMATOGRAPHY B
    
    G. Aymard et al., "Determination of twelve antiretroviral agents in human plasma sample usingreversed-phase high-performance liquid chromatography", J CHROMAT B, 744(2), 2000, pp. 227-240
28. Strisovsky, K; Tessmer, U; Langner, J; Konvalinka, J; Krausslich, HG
    Systematic mutational analysis of the active-site threonine of HIV-1 proteinase: Rethinking the "fireman's grip" hypothesis
    PROTEIN SCIENCE
    
    K. Strisovsky et al., "Systematic mutational analysis of the active-site threonine of HIV-1 proteinase: Rethinking the "fireman's grip" hypothesis", PROTEIN SCI, 9(9), 2000, pp. 1631-1641
29. Collinsova, M; Jiracek, J
    Phosphinic acid compounds in biochemistry, biology and medicine
    CURRENT MEDICINAL CHEMISTRY
    
    M. Collinsova e J. Jiracek, "Phosphinic acid compounds in biochemistry, biology and medicine", CURR MED CH, 7(6), 2000, pp. 629-647
30. Jalaie, M; Erickson, JA
    Homology model directed alignment selection for comparative molecular field analysis: Application to photosystem II inhibitors
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
    
    M. Jalaie e J.A. Erickson, "Homology model directed alignment selection for comparative molecular field analysis: Application to photosystem II inhibitors", J COMPUT A, 14(2), 2000, pp. 181-197
31. Shiraki, N; Hamada, A; Yasuda, K; Fujii, J; Arimori, K; Nakano, M
    Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins
    BIOLOGICAL & PHARMACEUTICAL BULLETIN
    
    N. Shiraki et al., "Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins", BIOL PHAR B, 23(12), 2000, pp. 1528-1531
32. Munshi, S; Chen, ZG; Yan, YW; Li, Y; Olsen, DB; Schock, HB; Galvin, BB; Dorsey, B; Kuo, LC
    An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease
    ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
    
    S. Munshi et al., "An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease", ACT CRYST D, 56, 2000, pp. 381-388
33. Fletcher, CV; Acosta, EP; Cheng, HL; Haubrich, R; Fischl, M; Raasch, R; Mills, C; Hu, XJ; Katzenstein, D; Remmel, RP; Gulick, RM
    Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884
    AIDS
    
    C.V. Fletcher et al., "Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884", AIDS, 14(16), 2000, pp. 2495-2501
34. Murphy, RL
    New antiretroviral drugs in development
    AIDS
    
    R.L. Murphy, "New antiretroviral drugs in development", AIDS, 14, 2000, pp. S227-S234
35. Newman, DJ; Cragg, GM; Snader, KM
    The influence of natural products upon drug discovery
    NATURAL PRODUCT REPORTS
    
    D.J. Newman et al., "The influence of natural products upon drug discovery", NAT PROD R, 17(3), 2000, pp. 215-234
36. Won, Y
    Binding free energy simulations of the HIV-1 protease and hydroxyethylene isostere inhibitors
    BULLETIN OF THE KOREAN CHEMICAL SOCIETY
    
    Y. Won, "Binding free energy simulations of the HIV-1 protease and hydroxyethylene isostere inhibitors", B KOR CHEM, 21(12), 2000, pp. 1207-1212
37. Wlodawer, A; Gustchina, A
    Structural and biochemical studies of retroviral proteases
    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY
    
    A. Wlodawer e A. Gustchina, "Structural and biochemical studies of retroviral proteases", BBA-PROT ST, 1477(1-2), 2000, pp. 16-34
38. Zheng, WF; Tropsha, A
    Novel variable selection quantitative structure-property relationship approach based on the k-nearest-neighbor principle
    JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES
    
    W.F. Zheng e A. Tropsha, "Novel variable selection quantitative structure-property relationship approach based on the k-nearest-neighbor principle", J CHEM INF, 40(1), 2000, pp. 185-194
39. Brophy, DF; Israel, DS; Pastor, A; Gillotin, C; Chittick, GE; Symonds, WT; Lou, Y; Sadler, BM; Polk, RE
    Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    
    D.F. Brophy et al., "Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers", ANTIM AG CH, 44(4), 2000, pp. 978-984
40. Shibata, N; Matsumura, Y; Okamoto, H; Kawaguchi, Y; Ohtani, A; Yoshikawa, Y; Takada, K
    Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: Study on combinations of two kinds of HIV-1 protease inhibitors
    JOURNAL OF PHARMACY AND PHARMACOLOGY
    
    N. Shibata et al., "Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: Study on combinations of two kinds of HIV-1 protease inhibitors", J PHARM PHA, 52(10), 2000, pp. 1239-1246
41. Wang, W; Kollman, PA
    Free energy calculations on dimer stability of the HIV protease using molecular dynamics and a continuum solvent model
    JOURNAL OF MOLECULAR BIOLOGY
    
    W. Wang e P.A. Kollman, "Free energy calculations on dimer stability of the HIV protease using molecular dynamics and a continuum solvent model", J MOL BIOL, 303(4), 2000, pp. 567-582
42. Figueiredo, LJO; Antunes, OAC
    Chemometric classification of HIV-1 protease inhibitors
    INTERNATIONAL JOURNAL OF QUANTUM CHEMISTRY
    
    L.J.O. Figueiredo e O.A.C. Antunes, "Chemometric classification of HIV-1 protease inhibitors", INT J QUANT, 76(6), 2000, pp. 744-755
43. Noble, S; Goa, KL
    Amprenavir - A review of its clinical potential in patients with HIV infection
    DRUGS
    
    S. Noble e K.L. Goa, "Amprenavir - A review of its clinical potential in patients with HIV infection", DRUGS, 60(6), 2000, pp. 1383-1410
44. Park, H; Suh, J; Lee, S
    Ab initio studies on the catalytic mechanism of aspartic proteinases: Nucleophilic versus general acid/general base mechanism
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
    
    H. Park et al., "Ab initio studies on the catalytic mechanism of aspartic proteinases: Nucleophilic versus general acid/general base mechanism", J AM CHEM S, 122(16), 2000, pp. 3901-3908
45. Langmann, P; Klinker, H; Schirmer, D; Zilly, M; Bienert, A; Richter, E
    High-performance liquid chromatographic method for the simultaneous determination of HIV-1 protease inhibitors indinavir, saquinavir and ritonavir inplasma of patients during highly active antiretroviral therapy
    JOURNAL OF CHROMATOGRAPHY B
    
    P. Langmann et al., "High-performance liquid chromatographic method for the simultaneous determination of HIV-1 protease inhibitors indinavir, saquinavir and ritonavir inplasma of patients during highly active antiretroviral therapy", J CHROMAT B, 735(1), 1999, pp. 41-50
46. Rose, MJ; Merschman, SA; Woolf, EJ; Matuszewski, BK
    Determination of L-756 423, a novel HIV protease inhibitor, in human plasma and urine using high-performance liquid chromatography with fluorescence detection
    JOURNAL OF CHROMATOGRAPHY B
    
    M.J. Rose et al., "Determination of L-756 423, a novel HIV protease inhibitor, in human plasma and urine using high-performance liquid chromatography with fluorescence detection", J CHROMAT B, 732(2), 1999, pp. 425-435
47. Louis, JM; Clore, GM; Gronenborn, AM
    Autoprocessing of HIV-1 protease is tightly coupled to protein folding
    NATURE STRUCTURAL BIOLOGY
    
    J.M. Louis et al., "Autoprocessing of HIV-1 protease is tightly coupled to protein folding", NAT ST BIOL, 6(9), 1999, pp. 868-875
48. Pai, VB; Nahata, MC
    Nelfinavir mesylate: A protease inhibitor
    ANNALS OF PHARMACOTHERAPY
    
    V.B. Pai e M.C. Nahata, "Nelfinavir mesylate: A protease inhibitor", ANN PHARMAC, 33(3), 1999, pp. 325-339
49. Ishima, R; Freedberg, DI; Wang, YX; Louis, JM; Torchia, DA
    Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function
    STRUCTURE WITH FOLDING & DESIGN
    
    R. Ishima et al., "Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function", STRUCT F D, 7(9), 1999, pp. 1047-1055
50. Xie, D; Gulnik, S; Gustchina, E; Yu, B; Shao, W; Qoronfleh, W; Nathan, A; Erickson, JW
    Drug resistance mutations can affect dimer stability of HIV-1 protease at neutral pH
    PROTEIN SCIENCE
    
    D. Xie et al., "Drug resistance mutations can affect dimer stability of HIV-1 protease at neutral pH", PROTEIN SCI, 8(8), 1999, pp. 1702-1707
51. Trylska, J; Antosiewicz, J; Geller, M; Hodge, CN; Klabe, RM; Head, MS; Gilson, MK
    Thermodynamic linkage between the binding of protons and inhibitors to HIV-1 protease
    PROTEIN SCIENCE
    
    J. Trylska et al., "Thermodynamic linkage between the binding of protons and inhibitors to HIV-1 protease", PROTEIN SCI, 8(1), 1999, pp. 180-195
52. Gatanaga, H; Aizawa, S; Kikuchi, Y; Tachikawa, N; Genka, I; Yoshizawa, S; Yamamoto, Y; Yasuoka, A; Oka, S
    Anti-HIV effect of saquinavir combined with ritonavir is limited by previous long-term therapy with protease inhibitors
    AIDS RESEARCH AND HUMAN RETROVIRUSES
    
    H. Gatanaga et al., "Anti-HIV effect of saquinavir combined with ritonavir is limited by previous long-term therapy with protease inhibitors", AIDS RES H, 15(17), 1999, pp. 1493-1498
53. Greenblatt, DJ; von Moltke, LL; Daily, JP; Harmatz, JS; Shader, RI
    Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: The clinical dilemma of concurrent inhibition and induction
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    
    D.J. Greenblatt et al., "Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: The clinical dilemma of concurrent inhibition and induction", J CL PSYCH, 19(4), 1999, pp. 293-296
54. van Heeswijk, RPG; Veldkamp, AI; Hoetelmans, RMW; Mulder, JW; Schreij, G; Hsu, A; Lange, JMA; Beijnen, JH; Meenhorst, PL
    The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals
    AIDS
    
    R.P.G. van Heeswijk et al., "The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals", AIDS, 13(14), 1999, pp. F95-F99
55. Lin, JH
    Role of pharmacokinetics in the discovery and development of indinavir
    ADVANCED DRUG DELIVERY REVIEWS
    
    J.H. Lin, "Role of pharmacokinetics in the discovery and development of indinavir", ADV DRUG DE, 39(1-3), 1999, pp. 33-49
56. Aungst, BJ
    P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs
    ADVANCED DRUG DELIVERY REVIEWS
    
    B.J. Aungst, "P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs", ADV DRUG DE, 39(1-3), 1999, pp. 105-116
57. Humphrey, RW; Wyvill, KM; Nguyen, BY; Shay, LE; Kohler, DR; Steinberg, SM; Ueno, T; Fukasawa, T; Shintani, M; Hayashi, H; Mitsuya, H; Yarchoan, R
    A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection
    ANTIVIRAL RESEARCH
    
    R.W. Humphrey et al., "A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection", ANTIVIR RES, 41(1), 1999, pp. 21-33
58. Yamaji, H; Matsumura, Y; Yoshikawa, Y; Takada, K
    Pharmacokinetic interactions between HIV-protease inhibitors in rats
    BIOPHARMACEUTICS & DRUG DISPOSITION
    
    H. Yamaji et al., "Pharmacokinetic interactions between HIV-protease inhibitors in rats", BIOPHARM DR, 20(5), 1999, pp. 241-247
59. Popov, ME; Kashparov, IV; Rumsh, LD; Popov, EM
    Mechanism of action of aspartyl proteases. VII. Noncovalent complexes of HIV-1 aspartic protease with substrate and substrate-like inhibitor
    BIOORGANICHESKAYA KHIMIYA
    
    M.E. Popov et al., "Mechanism of action of aspartyl proteases. VII. Noncovalent complexes of HIV-1 aspartic protease with substrate and substrate-like inhibitor", BIOORG KHIM, 25(12), 1999, pp. 911-922
60. Davit, B; Reynolds, K; Yuan, R; Ajayi, F; Conner, D; Fadiran, E; Gillespie, B; Sahajwalla, C; Huang, SM; Lesko, LJ
    FDA evaluations using in vitro metabolism to predict and interpret in vivometabolic drug-drug interactions: Impact on labeling
    JOURNAL OF CLINICAL PHARMACOLOGY
    
    B. Davit et al., "FDA evaluations using in vitro metabolism to predict and interpret in vivometabolic drug-drug interactions: Impact on labeling", J CLIN PHAR, 39(9), 1999, pp. 899-910
61. Huang, SM; Lesko, LJ; Williams, RL
    Assessment of the quality and quantity of drug-drug interaction studies inrecent NDA submissions: Study design and data analysis issues
    JOURNAL OF CLINICAL PHARMACOLOGY
    
    S.M. Huang et al., "Assessment of the quality and quantity of drug-drug interaction studies inrecent NDA submissions: Study design and data analysis issues", J CLIN PHAR, 39(10), 1999, pp. 1006-1014
62. Kumar, GN; Dykstra, J; Roberts, EM; Jayanti, VK; Hickman, D; Uchic, J; Yao, Y; Surber, B; Thomas, S; Granneman, GR
    Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction
    DRUG METABOLISM AND DISPOSITION
    
    G.N. Kumar et al., "Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction", DRUG META D, 27(8), 1999, pp. 902-908
63. Kumar, GN; Jayanti, V; Lee, RD; Whittern, DN; Uchic, J; Thomas, S; Johnson, P; Grabowski, B; Sham, H; Betebenner, D; Kempf, DJ; Denissen, JF
    In vitro metabolism of the HIV-1 protease inhibitor ABT-378: Species comparison and metabolite identification
    DRUG METABOLISM AND DISPOSITION
    
    G.N. Kumar et al., "In vitro metabolism of the HIV-1 protease inhibitor ABT-378: Species comparison and metabolite identification", DRUG META D, 27(1), 1999, pp. 86-91
64. Aguilar, N; Moyano, A; Pericas, MA; Riera, A
    A convergent, stereocontrolled synthesis of C-2-symmetrical and pseudosymmetrical sulfur-tethered bis(amino alcohols)
    TETRAHEDRON LETTERS
    
    N. Aguilar et al., "A convergent, stereocontrolled synthesis of C-2-symmetrical and pseudosymmetrical sulfur-tethered bis(amino alcohols)", TETRAHEDR L, 40(20), 1999, pp. 3913-3916
65. Gutmann, H; Fricker, G; Drewe, J; Toeroek, M; Miller, DS
    Interactions of HIV protease inhibitors with ATP-dependent drug export proteins
    MOLECULAR PHARMACOLOGY
    
    H. Gutmann et al., "Interactions of HIV protease inhibitors with ATP-dependent drug export proteins", MOLEC PHARM, 56(2), 1999, pp. 383-389
66. Yeh, KC; Stone, JA; Carides, AD; Rolan, P; Woolf, E; Ju, WD
    Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique:Study design and model-independent data analysis
    JOURNAL OF PHARMACEUTICAL SCIENCES
    
    K.C. Yeh et al., "Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique:Study design and model-independent data analysis", J PHARM SCI, 88(5), 1999, pp. 568-573
67. Klopman, G; Tu, M
    Diversity analysis of 14 156 molecules tested by the National Cancer Institute for anti-HIV activity using the quantitative structure-activity relational expert system MCASE
    JOURNAL OF MEDICINAL CHEMISTRY
    
    G. Klopman e M. Tu, "Diversity analysis of 14 156 molecules tested by the National Cancer Institute for anti-HIV activity using the quantitative structure-activity relational expert system MCASE", J MED CHEM, 42(6), 1999, pp. 992-998
68. Hulten, J; Andersson, HO; Schaal, W; Danielson, HU; Classon, B; Kvarnstrom, I; Karlen, A; Unge, T; Samuelsson, B; Hallberg, A
    Inhibitors of the C-2-symmetric HIV-1 protease: Nonsymmetric binding of a symmetric cyclic sulfamide with ketoxime groups in the P2/P2 ' side chains
    JOURNAL OF MEDICINAL CHEMISTRY
    
    J. Hulten et al., "Inhibitors of the C-2-symmetric HIV-1 protease: Nonsymmetric binding of a symmetric cyclic sulfamide with ketoxime groups in the P2/P2 ' side chains", J MED CHEM, 42(20), 1999, pp. 4054-4061
69. De Lucca, GV; Liang, J; De Lucca, I
    Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors
    JOURNAL OF MEDICINAL CHEMISTRY
    
    G.V. De Lucca et al., "Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors", J MED CHEM, 42(1), 1999, pp. 135-152
70. Berry, C; Humphreys, MJ; Matharu, P; Granger, R; Horrocks, P; Moon, RP; Certa, U; Ridley, RG; Bur, D; Kay, J
    A distinct member of the aspartic proteinase gene family from the human malaria parasite Plasmodium falciparum
    FEBS LETTERS
    
    C. Berry et al., "A distinct member of the aspartic proteinase gene family from the human malaria parasite Plasmodium falciparum", FEBS LETTER, 447(2-3), 1999, pp. 149-154
71. Mahalingam, B; Louis, JM; Reed, CC; Adomat, JM; Krouse, J; Wang, YF; Harrison, RW; Weber, IT
    Structural and kinetic analysis of drug resistant mutants of HIV-1 protease
    EUROPEAN JOURNAL OF BIOCHEMISTRY
    
    B. Mahalingam et al., "Structural and kinetic analysis of drug resistant mutants of HIV-1 protease", EUR J BIOCH, 263(1), 1999, pp. 238-245
72. Michelet, C; Bellissant, E; Ruffault, A; Arvieux, C; Delfraissy, JF; Raffi, F; Bazin, C; Renard, I; Sebille, V; Chauvin, JP; Dohin, E; Cartier, F
    Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine
    CLINICAL PHARMACOLOGY & THERAPEUTICS
    
    C. Michelet et al., "Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine", CLIN PHARM, 65(6), 1999, pp. 661-671
73. Garg, R; Gupta, SP; Gao, H; Babu, MS; Debnath, AK; Hansch, C
    Comparative quantitative structure-activity relationship studies on anti-HIV drugs
    CHEMICAL REVIEWS
    
    R. Garg et al., "Comparative quantitative structure-activity relationship studies on anti-HIV drugs", CHEM REV, 99(12), 1999, pp. 3525-3601
74. Martin, JL; Begun, J; Schindeler, A; Wickramasinghe, WA; Alewood, D; Alewood, PF; Bergman, DA; Brinkworth, RI; Abbenante, G; March, DR; Reid, RC; Fairlie, DP
    Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease
    BIOCHEMISTRY
    
    J.L. Martin et al., "Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease", BIOCHEM, 38(25), 1999, pp. 7978-7988
75. Drewe, J; Gutmann, H; Fricker, G; Torok, M; Beglinger, C; Huwyler, J
    HIV protease inhibitor ritonavir: A more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833
    BIOCHEMICAL PHARMACOLOGY
    
    J. Drewe et al., "HIV protease inhibitor ritonavir: A more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833", BIOCH PHARM, 57(10), 1999, pp. 1147-1152
76. Short, GF; Lodder, M; Laikhter, AL; Arslan, T; Hecht, SM
    Caged HIV-1 protease: Dimerization is independent of the ionization state of the active site aspartates
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
    
    G.F. Short et al., "Caged HIV-1 protease: Dimerization is independent of the ionization state of the active site aspartates", J AM CHEM S, 121(2), 1999, pp. 478-479
77. RODGERS JD; LAM PYS; JOHNSON BL; WANG HS; KO SS; SEITZ SP; TRAINOR GL; ANDERSON PS; KLABE RM; BACHELER LT; CORDOVA B; GARBER S; REID C; WRIGHT MR; CHANG CH; ERICKSONVIITANEN S
    DESIGN AND SELECTION OF DMP-850 AND DMP-851 - THE NEXT-GENERATION OF CYCLIC UREA HIV PROTEASE INHIBITORS
    Chemistry & biology
    
    J.D. Rodgers et al., "DESIGN AND SELECTION OF DMP-850 AND DMP-851 - THE NEXT-GENERATION OF CYCLIC UREA HIV PROTEASE INHIBITORS", Chemistry & biology, 5(10), 1998, pp. 597-608
78. PATEL M; KALTENBACH RF; NUGIEL DA; MCHUGH RJ; JADHAV PK; BACHELER LT; CORDOVA BC; KLABE RM; ERICKSONVIITANEN S; GARBER S; REID C; SEITZ SP
    THE SYNTHESIS OF SYMMETRICAL AND UNSYMMETRICAL P1 P1' CYCLIC UREAS ASHIV PROTEASE INHIBITORS/
    Bioorganic & medicinal chemistry letters
    
    M. Patel et al., "THE SYNTHESIS OF SYMMETRICAL AND UNSYMMETRICAL P1 P1' CYCLIC UREAS ASHIV PROTEASE INHIBITORS/", Bioorganic & medicinal chemistry letters, 8(9), 1998, pp. 1077-1082
79. PATEL M; BACHELER LT; RAYNER MM; CORDOVA BC; KLABE RM; ERICKSONVIITANEN S; SEITZ SP
    THE SYNTHESIS AND EVALUATION OF CYCLIC UREAS AS HIV PROTEASE INHIBITORS - MODIFICATIONS OF THE P1 P1' RESIDUES/
    Bioorganic & medicinal chemistry letters
    
    M. Patel et al., "THE SYNTHESIS AND EVALUATION OF CYCLIC UREAS AS HIV PROTEASE INHIBITORS - MODIFICATIONS OF THE P1 P1' RESIDUES/", Bioorganic & medicinal chemistry letters, 8(7), 1998, pp. 823-828
80. Chen, XQ; Kempf, DJ; Sham, HL; Green, BE; Molla, A; Korneyeva, M; Vasavanonda, S; Wideburg, NE; Saldivar, A; Marsh, KC; McDonald, E; Norbeck, DW
    Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P-3 ligands
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    
    X.Q. Chen et al., "Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P-3 ligands", BIOORG MED, 8(24), 1998, pp. 3531-3536
81. Han, W; Pelletier, JC; Hodge, CN
    Tricyclic ureas: A new class of HIV-1 protease inhibitors
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    
    W. Han et al., "Tricyclic ureas: A new class of HIV-1 protease inhibitors", BIOORG MED, 8(24), 1998, pp. 3615-3620
82. Ulysse, LG; Chmielewski, J
    Restricting the flexibility of crosslinked, interfacial peptide inhibitorsof HIV-1 protease
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    
    L.G. Ulysse e J. Chmielewski, "Restricting the flexibility of crosslinked, interfacial peptide inhibitorsof HIV-1 protease", BIOORG MED, 8(22), 1998, pp. 3281-3286
83. ZUTSHI R; SHULTZ MD; ULYSSE L; LUTGRING R; BISHOP P; SCHWEITZER B; VOGEL K; FRANCISKOVICH J; WILSON M; CHMIELEWSKI J
    INHIBITING THE DIMERIZATION OF HIV-1 PROTEASE
    Synlett
    
    R. Zutshi et al., "INHIBITING THE DIMERIZATION OF HIV-1 PROTEASE", Synlett, (10), 1998, pp. 1040
84. OPREA TI; MARSHALL GR
    RECEPTOR-BASED PREDICTION OF BINDING AFFINITIES
    Perspectives in drug discovery and design
    
    T.I. Oprea e G.R. Marshall, "RECEPTOR-BASED PREDICTION OF BINDING AFFINITIES", Perspectives in drug discovery and design, 9-11, 1998, pp. 35-61
85. HOLLOWAY MK
    A-PRIORI PREDICTION OF LIGAND AFFINITY BY ENERGY MINIMIZATION
    Perspectives in drug discovery and design
    
    M.K. Holloway, "A-PRIORI PREDICTION OF LIGAND AFFINITY BY ENERGY MINIMIZATION", Perspectives in drug discovery and design, 9-11, 1998, pp. 63-84
86. MARTIN YC
    3D QSAR - CURRENT STATE, SCOPE, AND LIMITATIONS
    Perspectives in drug discovery and design
    
    Y.C. Martin, "3D QSAR - CURRENT STATE, SCOPE, AND LIMITATIONS", Perspectives in drug discovery and design, 12, 1998, pp. 3-23
87. NORINDER U
    RECENT PROGRESS IN COMFA METHODOLOGY AND RELATED TECHNIQUES
    Perspectives in drug discovery and design
    
    U. Norinder, "RECENT PROGRESS IN COMFA METHODOLOGY AND RELATED TECHNIQUES", Perspectives in drug discovery and design, 12, 1998, pp. 25-39
88. LIN JH; LU AYH
    INHIBITION AND INDUCTION OF CYTOCHROME-P450 AND THE CLINICAL IMPLICATIONS
    Clinical pharmacokinetics
    
    J.H. Lin e A.Y.H. Lu, "INHIBITION AND INDUCTION OF CYTOCHROME-P450 AND THE CLINICAL IMPLICATIONS", Clinical pharmacokinetics, 35(5), 1998, pp. 361-390
89. KEMPF DJ; RODE RA; XU Y; SUN E; HEATHCHIOZZI ME; VALDES J; JAPOUR AJ; DANNER S; BOUCHER C; MOLLA A; LEONARD JM
    THE DURATION OF VIRAL SUPPRESSION DURING PROTEASE INHIBITOR THERAPY FOR HIV-1 INFECTION IS PREDICTED BY PLASMA HIV-1 RNA AT THE NADIR
    AIDS
    
    D.J. Kempf et al., "THE DURATION OF VIRAL SUPPRESSION DURING PROTEASE INHIBITOR THERAPY FOR HIV-1 INFECTION IS PREDICTED BY PLASMA HIV-1 RNA AT THE NADIR", AIDS, 12(5), 1998, pp. 9-14
90. MOLLA A; GRANNEMAN GR; SUN E; KEMPF DJ
    RECENT DEVELOPMENTS IN HIV PROTEASE INHIBITOR THERAPY
    Antiviral research
    
    A. Molla et al., "RECENT DEVELOPMENTS IN HIV PROTEASE INHIBITOR THERAPY", Antiviral research, 39(1), 1998, pp. 1-23
91. RACE EM; ADELSONMITTY J; KRIEGEL GR; BARLAM TF; REIMANN KA; LETVIN NL; JAPOUR AJ
    FOCAL MYCOBACTERIAL LYMPHADENITIS FOLLOWING INITIATION OF PROTEASE-INHIBITOR THERAPY IN PATIENTS WITH ADVANCED HIV-1 DISEASE
    Lancet
    
    E.M. Race et al., "FOCAL MYCOBACTERIAL LYMPHADENITIS FOLLOWING INITIATION OF PROTEASE-INHIBITOR THERAPY IN PATIENTS WITH ADVANCED HIV-1 DISEASE", Lancet, 351(9098), 1998, pp. 252-255
92. HSU A; GRANNEMAN GR; CAO GL; CAROTHERS L; JAPOUR A; ELSHOURBAGY T; DENNIS S; BERG J; ERDMAN K; LEONARD JM; SUN EG
    PHARMACOKINETIC INTERACTION BETWEEN RITONAVIR AND INDINAVIR IN HEALTHY-VOLUNTEERS
    Antimicrobial agents and chemotherapy
    
    A. Hsu et al., "PHARMACOKINETIC INTERACTION BETWEEN RITONAVIR AND INDINAVIR IN HEALTHY-VOLUNTEERS", Antimicrobial agents and chemotherapy, 42(11), 1998, pp. 2784-2791
93. LIARD F; JARAMILLO J; PARIS WL; YOAKIM C
    PHARMACOKINETIC ASPECTS OF PALINAVIR, AN HIV PROTEASE INHIBITOR, IN SPRAGUE-DAWLEY RATS
    Journal of pharmaceutical sciences
    
    F. Liard et al., "PHARMACOKINETIC ASPECTS OF PALINAVIR, AN HIV PROTEASE INHIBITOR, IN SPRAGUE-DAWLEY RATS", Journal of pharmaceutical sciences, 87(6), 1998, pp. 782-785
94. WACHER VJ; SILVERMAN JA; ZHANG YC; BENET LZ
    ROLE OF P-GLYCOPROTEIN AND CYTOCHROME-P450 3A IN LIMITING ORAL ABSORPTION OF PEPTIDES AND PEPTIDOMIMETICS
    Journal of pharmaceutical sciences
    
    V.J. Wacher et al., "ROLE OF P-GLYCOPROTEIN AND CYTOCHROME-P450 3A IN LIMITING ORAL ABSORPTION OF PEPTIDES AND PEPTIDOMIMETICS", Journal of pharmaceutical sciences, 87(11), 1998, pp. 1322-1330
95. VONMOLTKE LL; GREENBLATT DJ; DUAN SX; DAILY JP; HARMATZ JS; SHADER RI
    INHIBITION OF DESIPRAMINE HYDROXYLATION (CYTOCHROME P450-2D6) IN-VITRO BY QUINIDINE AND BY VIRAL PROTEASE INHIBITORS - RELATION TO DRUG-INTERACTIONS IN-VIVO
    Journal of pharmaceutical sciences
    
    L.L. Vonmoltke et al., "INHIBITION OF DESIPRAMINE HYDROXYLATION (CYTOCHROME P450-2D6) IN-VITRO BY QUINIDINE AND BY VIRAL PROTEASE INHIBITORS - RELATION TO DRUG-INTERACTIONS IN-VIVO", Journal of pharmaceutical sciences, 87(10), 1998, pp. 1184-1189
96. KEMPF DJ; SHAM HL; MARSH KC; FLENTGE CA; BETEBENNER D; GREEN BE; MCDONALD E; VASAVANONDA S; SALDIVAR A; WIDEBURG NE; KATI WM; RUIZ L; ZHAO C; FINO LM; PATTERSON J; MOLLA A; PLATTNER JJ; NORBECK DW
    DISCOVERY OF RITONAVIR, A POTENT INHIBITOR OF HIV PROTEASE WITH HIGH ORAL BIOAVAILABILITY AND CLINICAL EFFICACY
    Journal of medicinal chemistry
    
    D.J. Kempf et al., "DISCOVERY OF RITONAVIR, A POTENT INHIBITOR OF HIV PROTEASE WITH HIGH ORAL BIOAVAILABILITY AND CLINICAL EFFICACY", Journal of medicinal chemistry, 41(4), 1998, pp. 602-617
97. TURNER SR; STROHBACH JW; TOMMASI RA; ARISTOFF PA; JOHNSON PD; SKULNICK HI; DOLAK LA; SEEST EP; TOMICH PK; BOHANAN MJ; HORNG MM; LYNN JC; CHONG KT; HINSHAW RR; WATENPAUGH KD; JANAKIRAMAN MN; THAISRIVONGS S
    TIPRANAVIR (PNU-140690) - A POTENT, ORALLY BIOAVAILABLE NONPEPTIDIC HIV PROTEASE INHIBITOR OF THE 5,6-DIHYDRO-4-HYDROXY-2-PYRONE SULFONAMIDE CLASS
    Journal of medicinal chemistry
    
    S.R. Turner et al., "TIPRANAVIR (PNU-140690) - A POTENT, ORALLY BIOAVAILABLE NONPEPTIDIC HIV PROTEASE INHIBITOR OF THE 5,6-DIHYDRO-4-HYDROXY-2-PYRONE SULFONAMIDE CLASS", Journal of medicinal chemistry, 41(18), 1998, pp. 3467-3476
98. DELUCCA GV; KIM UT; LIANG J; CORDOVA B; KLABE RM; GARBER S; BACHELER LT; LAM GN; WRIGHT MR; LOGUE KA; ERICKSONVIITANEN S; KO SS; TRAINOR GL
    NONSYMMETRIC P2 P2' CYCLIC UREA HIV PROTEASE INHIBITORS - STRUCTURE-ACTIVITY RELATIONSHIP, BIOAVAILABILITY, AND RESISTANCE PROFILE OF MONOINDAZOLE-SUBSTITUTED P2 ANALOGS/
    Journal of medicinal chemistry
    
    G.V. Delucca et al., "NONSYMMETRIC P2 P2' CYCLIC UREA HIV PROTEASE INHIBITORS - STRUCTURE-ACTIVITY RELATIONSHIP, BIOAVAILABILITY, AND RESISTANCE PROFILE OF MONOINDAZOLE-SUBSTITUTED P2 ANALOGS/", Journal of medicinal chemistry, 41(13), 1998, pp. 2411-2423
99. HAN Q; CHANG CH; LI RH; RU Y; JADHAV PK; LAM PYS
    CYCLIC HIV PROTEASE INHIBITORS - DESIGN AND SYNTHESIS OF ORALLY BIOAVAILABLE, PYRAZOLE P2 P2' CYCLIC UREAS WITH IMPROVED POTENCY/
    Journal of medicinal chemistry
    
    Q. Han et al., "CYCLIC HIV PROTEASE INHIBITORS - DESIGN AND SYNTHESIS OF ORALLY BIOAVAILABLE, PYRAZOLE P2 P2' CYCLIC UREAS WITH IMPROVED POTENCY/", Journal of medicinal chemistry, 41(12), 1998, pp. 2019-2028
100. ALA PJ; DELOSKEY RJ; HUSTON EE; JADHAV PK; LAM PYS; EYERMANN CJ; HODGE CN; SCHADT MC; LEWANDOWSKI FA; WEBER PC; MCCABE DD; DUKE JL; CHANG CH
     MOLECULAR RECOGNITION OF CYCLIC UREA HIV-1 PROTEASE INHIBITORS
     The Journal of biological chemistry
     
     P.J. Ala et al., "MOLECULAR RECOGNITION OF CYCLIC UREA HIV-1 PROTEASE INHIBITORS", The Journal of biological chemistry, 273(20), 1998, pp. 12325-12331